Please assess the completion status of the following clinical trial:

Trial Title: Concurrent Bupropion / Varenicline for Smoking Cessation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* 18-65 years old;~* smoked an average of at least 10 cigarettes per day for three cumulative years;~* have an expired air CO reading assessed at screening of at least 10ppm;~* express a desire to quit smoking within the next 30 days.~Exclusion Criteria:~* Hypertension (systolic \>140 mm Hg, diastolic \>100 mm Hg, coupled with a history of hypertension); subjects with no previous diagnosis of hypertension may have a screening blood pressure up to 160/100.~* Hypotension with symptoms (systolic \<90 mm Hg, diastolic \<60 mm Hg).~* Coronary heart disease;~* Lifetime history of heart attack;~* Cardiac rhythm disorder (irregular heart rhythm);~* Chest pains (unless history, exam, and ECG clearly indicate a non-cardiac source);~* Cardiac (heart) disorder (including but not limited to valvular heart disease, heart murmur, heart failure);~* History of skin allergy;~* Active skin disorder (e.g., psoriasis) within the last five years, except minor skin conditions (including but not limited to facial acne, minor localized infections, and superficial minor wounds);~* Liver or kidney disorder (except kidney stones, gallstones);~* Gastrointestinal problems or disease other than gastroesophageal reflux or heartburn;~* Active ulcers in the past 30 days;~* Currently symptomatic lung disorder/disease (including but not limited to chronic obstructive pulmonary disease (COPD), emphysema, and asthma);~* Brain abnormality (including but not limited to stroke, brain tumor, and seizure disorder);~* Migraine headaches that occur more frequently than once per week;~* Recent, unexplained fainting spells;~* Problems giving blood samples;~* Diabetes treated with insulin; non-insulin treated diabetes (unless glucose is less than 180mg/dcl and HbA1c is less than 7%);~* Current cancer or treatment for cancer in the past six months (except basal or squamous cell skin cancer);~* Other major medical condition;~* Current psychiatric disease (with the exception of anxiety disorders, obsessive compulsive disorder (OCD) and ADHD);~* Suicidal ideation (within the past 10 years) or lifetime occurrence of attempted suicide;~* Current depression;~* Bulimia or anorexia;~* Pregnant or nursing mothers;~* Alcohol abuse;~* Use of Opiate medications for pain or sleep in the past 14 days;~* Significant adverse reaction to nicotine patches, nicotine inhalers, bupropion / Wellbutrin / Zyban or Chantix / Varenicline in the past.~* Use (within the past 30 days) of:~* Illegal drugs (or if the urine drug screen is positive),~* Experimental (investigational) drugs;~* Psychiatric medications including antidepressants, anti-psychotics or any other medications that are known to affect smoking cessation (e.g. clonidine);~* Smokeless tobacco (chewing tobacco, snuff), cigars, pipes or e-cigarettes;~* Wellbutrin, bupropion, Zyban, Chantix, nicotine replacement therapy or any other smoking cessation aid.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- varenicline (Type: ACTIVE_COMPARATOR): This group will consist of smokers who, based on smoking behavior, DO NOT respond favorably to pre-cessation nicotine patches (assessed at Session P2). They will receive varenicline.
- Nicotine Patches only (Type: ACTIVE_COMPARATOR): This group will consist of smokers who, based on smoking behavior, respond favorably to pre-cessation nicotine patches(assessed at Session P2). They will continue to receive only nicotine patches.
- Nicotine Patches with Nicotine Inhaler (Type: ACTIVE_COMPARATOR): This group will consist of smokers who, based on smoking behavior, respond favorably to pre-cessation nicotine patches (assessed at Session P2). They will continue to receive nicotine patches and will receive a nicotine inhaler to use as needed after their quit date.
- varenicline with bupropion (Type: ACTIVE_COMPARATOR): This group will consist of smokers who, based on smoking behavior, DO NOT respond favorably to pre-cessation nicotine patches (assessed at Session P2). They will receive varenicline in combination with bupropion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete